SPY421.97-0.14 -0.03%
DIA338.65-2.11 -0.62%
IXIC14,161.35+121.67 0.87%

BRIEF-Inflarx NV - Announces Positive Topline Results For Vilobelimab From U.S. Phase Ii Anca-Associated Vasculitis Ixplore Study

05/11/2021 16:53
BRIEF-Inflarx NV - Announces Positive Topline Results For Vilobelimab From U.S. Phase Ii Anca-Associated Vasculitis Ixplore Study

- Inflarx NV IF0G.DE:

  • INFLARX NV - ANNOUNCES POSITIVE TOPLINE RESULTS FOR VILOBELIMAB FROM U.S. PHASE II ANCA-ASSOCIATED VASCULITIS IXPLORE STUDY

  • INFLARX NV - U.S. IXPLORE PHASE II TRIAL ACHIEVED ITS OBJECTIVE

  • INFLARX NV - VILOBELIMAB WAS SHOWN TO BE SAFE AND WELL TOLERATED IN PATIENTS WITH ANCA-ASSOCIATED VASCULITIS WHEN ADDED TO CURRENT STANDARD OF CARE

  • INFLARX NV - EU IXCHANGE PHASE II TRIAL IS FULLY ENROLLED WITH RESULTS EXPECTED BY END OF 2021

Source text for Eikon: ID:nGNX4jFZHX

Further company coverage: IF0G.DE


(([email protected];))